+ Follow PROFESS Tag
Array
(
[results] => Array
(
[0] => Array
(
[ArticleID] => 568653
[Title] => The devil is content to let us profess Christianity as long as we do not practice it.
[Summary] => The devil is content to let us profess Christianity as long as we do not practice it.
[DatePublished] => 2010-04-23 00:00:00
[ColumnID] => 133272
[Focus] => 0
[AuthorID] =>
[AuthorName] =>
[SectionName] => Word of the day
[SectionUrl] => word-of-the-day
[URL] =>
)
[1] => Array
(
[ArticleID] => 226916
[Title] => First patient enrolled in stroke prevention trial
[Summary] => The first patient has been enrolled in the Prevention Regimen For Effectively avoiding Second Strokes (PRoFESS) trial four weeks earlier than initially planned.
PRoFESS, the largest-ever secondary stroke prevention trial, will include a total of 15,500 patients in about 600 sites in more than 20 countries.
The principal investigator, Prof. Hans-Christoph Diener, randomized the first patient at the University of Essen in Germany.
[DatePublished] => 2003-11-06 00:00:00
[ColumnID] => 133272
[Focus] => 0
[AuthorID] =>
[AuthorName] =>
[SectionName] => Science and Environment
[SectionUrl] => science-and-environment
[URL] =>
)
)
)
PROFESS
Array
(
[results] => Array
(
[0] => Array
(
[ArticleID] => 568653
[Title] => The devil is content to let us profess Christianity as long as we do not practice it.
[Summary] => The devil is content to let us profess Christianity as long as we do not practice it.
[DatePublished] => 2010-04-23 00:00:00
[ColumnID] => 133272
[Focus] => 0
[AuthorID] =>
[AuthorName] =>
[SectionName] => Word of the day
[SectionUrl] => word-of-the-day
[URL] =>
)
[1] => Array
(
[ArticleID] => 226916
[Title] => First patient enrolled in stroke prevention trial
[Summary] => The first patient has been enrolled in the Prevention Regimen For Effectively avoiding Second Strokes (PRoFESS) trial four weeks earlier than initially planned.
PRoFESS, the largest-ever secondary stroke prevention trial, will include a total of 15,500 patients in about 600 sites in more than 20 countries.
The principal investigator, Prof. Hans-Christoph Diener, randomized the first patient at the University of Essen in Germany.
[DatePublished] => 2003-11-06 00:00:00
[ColumnID] => 133272
[Focus] => 0
[AuthorID] =>
[AuthorName] =>
[SectionName] => Science and Environment
[SectionUrl] => science-and-environment
[URL] =>
)
)
)
abtest
November 6, 2003 - 12:00am